From today's Times:

Tiddler to watch

"ImmuPharma, steady at 46p, the biotech group which has a treatment of the disease Lupus in phase II trials, could benefit from the failure this week of trials of rival drug Rituxan. ImmuPharma's housebroker, Panmure Gordon, believes its client may attract the attention of Rituxan's developers, Genentech and Biogen Idec."

OK, I know we're all heartily sick of the promising small pharmacos, but I thought I'd bring this one to your attention because the demise of one much-hyped drug can indeed have a positive knock-on effect elsewhere. Furthermore, there doesn't seem to be much medication out there for Lupus.

This company is run by experienced people who have previously worked for some of the majors like GSK, Bristol-Myers Squibb, etc, and in investment banking. Their research results have been positive so far.

I made a good profit on these last year and the sp seems to have turned up again recently. Bought back again this morning. (NB: too small to trade in CFDs)

Full-year Prelims out today. Ciick on link:

Immupharma Full-Year Prelims

Glad I bought back in a few days ago - showing a good profit and I'm sure will have further to go.

Come and meet your CEO!

One2One Investor Presentation Invitation

Thursday 15th October

Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB Starting at 6pm



One2One investor forum on Thursday 15th October, the directors of Lipoxen Plc (AIM: LPX), Plant Impact (AIM: PIM) and ImmuPharma PLC (AIM: IMM) will be presenting

The presentations will start at 6:00pm and finish at approx 7:30pm. Following the presentations will be a complimentary bar and an assortment of the finest seasonal hot & cold canap giving you the opportunity to speak with the directors and other investors. It is expected that this forum will be oversubscribed, so please register to avoid disappointment.


Register Here - http://www.sign-up.to/signup.php?fid=1865&pid=7163


If you have any problems registering or queries please email action@proactiveinvestors.com


These are superb events held in a wonderful setting in Mayfair, where private investors mingle with city professionals and network after the presentations.

The nearest tube statons are Green Park and Bond Street, which are five and seven minute walks away from the hotel respectively.



Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms from which it has already progressed two products into clinical development. The first, SuliXen, is a long-acting insulin and the second, ErepoXen, is a long-acting erythropoietin (EPO). Lipoxen’s preclinical pipeline includes Factor XIII and vaccines against HIV, influenza and malaria. The Company has a low-risk business model and currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited, Genentech, Amgen and Genzyme.



Plant Impact specialises in plant stress relief. Plant Impact provide a dynamic and uncompromising new approach to crop nutrition and crop health, giving growers significantly increased marketable yields, more consistent quality with reduced environmental impact, leading to the ethically grown food demanded by consumers and the food chain.




ImmuPharma plc is a drug discovery and development company. The Company, along with its subsidiaries, is principally engaged in investing in pharmaceutical research and development companies. The Company has operations in Mulhouse, France and Basle, Switzerland. The ImmuPharma plc focuses to develop drugs to treat serious medical conditions. It has five drugs in development to treat: lupus, cancer, severe pain, highly resistant infections, such as methicillin-resistant staphylococcus aureus (MRSA) and inflammatory and allergic disorders. ImmuPharma was this week rated a ‘buy’ at Matrix with a 309p/share target price. ImmuPharma is currently trading at 85p

noble brokers target 220 p and could be 10 .read in one of articles in newspaper articles today forget where

They were magnificent results a couple of weeks ago and in a normal market I would have bought them when they dropped to the mid 80's which was ridiculous.

As you can gather I didn't as I didn't want my money tied up in a stock that wasn't moving.

Wish I had now! lol

Today's RNS:
ImmuPharma wins 'Best Technology 2009' Award at the AIM Awards

ImmuPharma PLC (LSE: IMM) the specialist discovery and development pharmaceutical company, has won the Best Technology Award at the AIM Awards 2009, organized by the London Stock Exchange.

The Award, announced at the AIM Awards Dinner in London on 15 October 2009, is presented to the company which reflects the innovation and entrepreneurial skills that are considered the cornerstone of the AIM culture.

Commenting on the award, Richard Warr, Chairman of ImmuPharma said: "ImmuPharma is honoured to receive the Best Technology Award at the 2009 AIM Awards Dinner. It is a prestigious award and I should like to thank the AIM community for recognising the innovation and entrepreneurial skills that have driven ImmuPharma forward over the last few years. This Award builds on our success at the European Mediscience Awards in June 2009 where ImmuPharma was awarded the Breakthrough of the Year Award. For ImmuPharma the journey is very much beginning and to have received such public recognition over the past year is particularly rewarding."

What a pleasant surprise to see today's rise - peaked at 140p but settled at 135p for now; up 10%. Could be something afoot.

This would explain yesterday's rise:

IMM - Positive results of Phase IIb trials

Hmm - back down it goes... Pity I wasn't around to keep an eye on this yesterday!

I don't often post, but this price drop doesn't make sense to me.

cont: The old adage of buy on rumour sell on news seems to have been over done here. Still, an opportunity to buy in again at sub 110p but I suspect we're going to trade sideways for some time once today's price settles.

Reckon you're right Lar... Probably be a while before we see a dramatic rise again but should be all right long term. They seem a well-run company with a good product

Well I doubled my holding during yesterday afternoon and broke one of my basic rules, i.e. never buy a falling share. So IMM is now more than 10% of my portfolio - another broken rule. Still, I feel less frustrated than yesterday . . . At least it didn't gap down first thing this morning as it did in July when the current charts have some similarities.

I reckon you were bowled a googly by the MM's Larboulois.

Was tempted to go in just before the close yesterday when it suddenly dipped to 105p but glad I resisted. Too many red herrings atm.

This really has got thumped today!

No it hasn't. Went down from 108p to about 106p.

More of a doosra than a googly Dealerdear.

As Ive already said, I dont normally post but Im early retired and sometimes I guess I let my heart rule my head. Now wheres this going youre wondering?

Allow me to tell you a little story. My wife has a very good friend whom she worked with for a long period of time. Weve lived in France for four years and Debbie her/our friend, frequently visits us. She separated from her partner about the same time as we came to France. Soon after this and following a number of tests she was diagnosed with lupus disease, an illness Id never heard of.

Im normally not sentimental about shares; Im a chartist and do lots of short term trades. I try to identify good points to enter and look for a quick 10 - 15% uplift and then Im out and looking elsewhere. Four years ago, I sold most of my shares save for some oil stocks when we came to live in France. I was very lucky because until this January, we didnt have a broadband connection in our village so most of my portfolio had been in cash for three years or so and I missed all the problems of last years slump. In June I restarted my subscriptions to real time prices etc. and started trading again. I came across ImmuPharma during September of this year, did some research not much I might add but I spotted that two directors had sold holdings of 10 million plus to M&G (so that was positive) and bought in three tranches (sorry French influence) in early October. This, after a fib retracement from the then September high, plus two other indicators I use which were about as good as they get. They rose very quickly to 120p mostly on two consecutive days mid month. But I then broke one of my rules and didnt sell; partly out of sentiment re Debbie and partly because I was up over 30% in less than a week, my best run ever on a supposedly short term trade. Over the next four weeks they tracked sideways and down 10% or so before breaking out above what I had as the 120.5p resistance line and seemingly off to new heights. On Wednesday of this week as they rocketed past 140p I began to doubt my carefully nurtured, regular trading system. I was now up 60% in little over 6 weeks. But this is where it went pear shaped because on Thursday morning after what I perceived to be an upbeat update on the Phase 11b trial , I bought in again, only to watch in astonishment as the rest of the day unfolded. Then as the price dropped below 110p, I made two more buys in the afternoon. This was a mistake within my own rules as noted by my own earlier posts about not buying falling shares and my thoughts that the share would now probably trade sideways. Under my rules, I dont buy shares that are falling or that I think will trade sideways. And therein lies the moral of the story. Stick to what youre good at and comfortable with and dont be greedy. And before somebody tells me Im well up with my trades - my frustration arises with me and not IMM. As I do my weekend resume, IMM now also holds another record in my current portfolio i.e. my biggest individual share price drop in a short period of time. And that is my frustration. Its not within my comfort zone. Logic dictates that I should sell all my holding on Monday morning, move elsewhere and wait for my indicators on IMM to come back together again. Sorry if Ive bored you good folk but Ive at least now Ive clarified my thoughts and got it off my chest. Now lets see if Prostrakan are worth another punt sometime this coming week.

Just read my last post - looks like something out of a Mills and Boon - not what this thread is about in some respects.

Yes - interesting novel Lar... But a really debilitating illness (I also know someone who suffers from it) and no 'pills' currently available.

According to The Times:
"ImmuPharma dropped 26p to 109p after the lupus specialist reported interim results for Lupuzor, its lead drug. The trial met its key target, but failed to meet statistical significance on one measurement."

Having re-read the RNS I still can't pinpoint the negative here, and wonder whether something may have come out at the conference call?

I don't think it could be anything too serious in the long-term, since all the primary endpoints were reached successfully, and were statistically significant.

From a pure trading point of view, it's a bore of course...

PSK yesterday joined IMM in 'keep clear territory' - my system of course.

Certainly wouldn't recommend buying just now. Took a profit yesterday, though should have done so earlier in the week... 85p is probably the level to watch out for and review before buying back in; could dip lower while we await further trial results next year.